Lilly appoints Lucas Montarce as executive vice president and chief financial officer
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has appointed Lucas Montarce as executive vice president and chief financial officer (CFO), effective immediately. Montarce, who joined Lilly in 2001, has held various finance leadership roles within the company, including group vice president, corporate controller, and CFO of Lilly Research Laboratories. He most recently served as Lilly president and general manager for the Spain, Portugal and Greece hub.
Montarce holds a bachelor's degree in business accounting from Catholic University (Argentina) and an MBA from the Center for Macroeconomic Studies of Argentina. CEO David A. Ricks expressed confidence in Montarce's abilities, citing his drive, curiosity, and integrity. Montarce stated his commitment to building on Lilly's strong financial foundation and driving continued success as the company expands its global footprint.
Positive
- Appointment of an experienced internal candidate as CFO
- New CFO has diverse finance leadership experience within the company
- Potential for seamless transition due to Montarce's familiarity with Lilly's operations
Negative
- None.
News Market Reaction
On the day this news was published, LLY gained 0.62%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manager for the
"We are excited to announce Lucas as Lilly's next CFO, following a competitive search across health care, tech and general industries," said David A. Ricks, chair and CEO. "Developing leadership talent has always been a strength for Lilly, and Lucas has thrived in a wide variety of roles of increasing scope and impact. Having worked directly with Lucas for more than a decade, I am highly confident he has the drive, curiosity and integrity to excel as our next CFO."
"I am committed to building on our strong financial foundation and helping drive continued success as we expand our global footprint and deliver long-term value to our stakeholders," said Montarce. "I am honored to step into this role during such a significant time in our company's history and look forward to working alongside the executive team and my talented Lilly finance colleagues."
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including about Lilly's leadership and the company's strategic plans, reflecting Lilly's current beliefs and expectations. However, there can be no assurances of achieved objectives or strategy execution as planned. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | |
Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-appoints-lucas-montarce-as-executive-vice-president-and-chief-financial-officer-302241110.html
SOURCE Eli Lilly and Company
FAQ
Who is the new CFO of Eli Lilly (LLY)?
What is Lucas Montarce's background at Eli Lilly (LLY)?
What educational qualifications does Eli Lilly's (LLY) new CFO have?
When did Lucas Montarce's appointment as CFO of Eli Lilly (LLY) take effect?
